Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga/64Cu-FAPI-XT117 PET/CT in Malignant Solid Tumors
NCT05814835Phase 1Completed
- Sponsor
- Chinese PLA General Hospital
- Start
- Dec 2022
- Primary completion
- Nov 2023
- Modality
- Radiopharmaceutical, Diagnostic, Positron Emission Tomography Imaging
- Countries
- 1
01
Overview
Phase 1, open-label trial of 68Ga-FAPI-XT117 and 64Cu-FAPI-XT117 in malignant solid tumor (3 arms), sponsored by Chinese PLA General Hospital. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 7 days. Started Dec 2022; status: completed.
02
Drugs
68Ga-FAPI-XT11764Cu-FAPI-XT117
03
Conditions
malignant solid tumor
Beyond the preview
Go deeper on NCT05814835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05814835.